Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
44,250
+1,300 (3.03%)
Last updated: Dec 10, 2025, 12:37 PM KST
126.00%
Market Cap619.88B
Revenue (ttm)n/a
Net Income (ttm)-39.26B
Shares Out14.43M
EPS (ttm)-2,755.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume768,101
Average Volume142,220
Open43,700
Previous Close42,950
Day's Range42,750 - 44,550
52-Week Range19,390 - 48,550
Beta1.49
RSI60.32
Earnings DateNov 13, 2025

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.